木瓜直播

New safety and efficacy data highlight potential, Emma Guttman-Yassky explains

Potential as first-line agent for mild to moderate cases, says Jonathan Silverberg

Responders saw reduced flaring at both 100 and 200 mg

"We finally have something that's not hydroquinone," says Noelani Gonzalez, MD

IL-36 receptor blocker tested in rare type of psoriasis

'New approaches haven't come out in decades,' says Joel Gelfand

Tina Alster, MD, explains how she incorporates the sessions into practice

Andrew Alexis, MD, discusses presentations from the Skin of Color Society and AAD

Dr. Lawrence Eichenfield, MD, looks forward to an FDA approval